12:00 AM
Oct 21, 2013
 |  BC Week In Review  |  Company News  |  Other News

XenoPort autoimmune, neurology news

XenoPort investor Clinton Group Inc. said the biotech's CEO Ronald Barrett should resign and called for a shift in the company's focus to XP23829, which is in Phase I testing for relapsing-remitting multiple sclerosis (RRMS) and in preclinical testing for psoriasis. In a letter to Barrett, Clinton Group said XenoPort's Horizant gabapentin enacarbil - which is approved in the U.S. to...

Read the full 303 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >